Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4215958 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4221934 | 1.00 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4230189 | 0.97 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4221936 | 0.95 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4215959 | 0.95 | ADORA2A (0.51) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3907187 | 0.92 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4230196 | 0.92 | ADORA2A (0.52) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4228236 | 0.91 | ADORA2A (0.56) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4229573 | 0.91 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL4232881 | 0.91 | ADORA2A (0.49) | ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018381-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-28 | — | — | EP | claimed |
| WO-2007121918-A2 | USE OF 2-(PURIN-9-YL)-TETRAHYDOFURAN-3,4-DIOL DERIVATIVES AS ADENOSINE A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | claimed |